A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lun...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Asahina, H, Yamazaki, K, Kinoshita, I, Sukoh, N, Harada, M, Yokouchi, H, Ishida, T, Ogura, S, Kojima, T, Okamoto, Y, Fujita, Y, Dosaka–akita, H, Isobe, H, Nishimura, M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2006
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360715/
https://ncbi.nlm.nih.gov/pubmed/17047648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603393
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares